Welcome to MyStrategist, the digital home for Market Pathways.

Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically. Subscribe Today

Browse   Latest Issue

Latest from Market Pathways

Global Medical Device Regulatory, Reimbursement, and Policy Review


Regulatory & Reimbursement

Going Local: Strategic Considerations for Medtech Manufacturers in China

A rise in regulatory policies in China favoring domestic products puts a premium on companies achieving some level of localization in the country. Establishing a China-based manufacturing footprint is crucial to this end, but the exact definition of “local” is evolving. Context and considerations from Grace Wang and Helen Chen at L.E.K. Consulting.

Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways

Start Trial

Latest from Market Pathways

Global Medical Device Regulatory, Reimbursement, and Policy Review

Regulatory & Reimbursement

Pathways Document Depot: Cataloging Medtech Policy

A sortable and searchable running inventory of global medtech regulatory and policy official documents, including rules, guidance documents, memos, white papers, and more from national authorities, non-governmental groups, and global organizations.

Don't Just Advertise... Strategize!

Advertise with MedTech Strategist and be seen by medtech's most influential executives.

Learn More
Latest from Market Pathways

Global Medical Device Regulatory, Reimbursement, and Policy Review


Discover the people, technologies, and companies in the global medical device industry that will impact your corporate strategy with MedTech Strategist.

Subscribe Now   Learn More
More From Market Pathways:

Industry Retains Hope as New MCIT Proposal Reaches White House OMB’s Desk

CMS has apparently produced a new proposed rule for the Medicare Coverage of Innovative Technology program and sent it for administrative vetting. It could be a positive sign for industry that some version of the automatic coverage pathway will make it over the finish line, but details remain thin and there are no assurances.

Read Article